Navigation Links
Senesco Technologies Initiates Preclinical Studies for Cancer Target
Date:12/5/2007

NEW BRUNSWICK, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today, that it has initiated preclinical lab studies at Mayo Clinic focused on multiple myeloma. These studies will further test the ability of Senesco's Factor 5A gene technology to up-regulate apoptosis of cancer cells. Additionally, the studies will evaluate delivery molecules for encapsulation of Factor 5A to enhance the time the gene will circulate in the bloodstream before clearance by the body.

The data gathered from these animal experiments, together with the results of other Factor 5A studies, will be reviewed to determine its sufficiency for submission of a protocol to Mayo Clinic for human studies and to the Food and Drug Administration for an Investigational New Drug Application.

Previously, Senesco has announced the results of experiments performed at Mayo Clinic on a human multiple myeloma cell line. In those experiments, treatment with Factor 5A caused significant increase in apoptosis of the cancer cells compared to the untreated cells.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harv
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:10/1/2014)... October 01, 2014 After undergoing a ... chamber of commerce to join, Living Well Assisted Living ... Commerce in Marin County, the home of its headquarters. ... the moment, and the thought of adding one more ... to keep looking for the right chamber to join ...
(Date:10/1/2014)... Angeles, CA (PRWEB) October 01, 2014 ... debut documentary film, "Beautiful Births", emerging filmmaker Jacqui Blue ... help other women discover the truth about natural birth. ... from people all over the world and has been ... birth. Many of the topics highlighted in the film ...
(Date:10/1/2014)... 2014 Indosoft, Inc., a leading provider of ... it has added support for Sangoma Lyra ... Indosoft have a history of bringing innovative products to ... offers a significant benefit to those using Asterisk as a ... available to users of Q-Suite. , In the past decades, ...
(Date:10/1/2014)... QueenBeeTickets.com is giving music fans the opportunity to purchase ... tour, which has him traveling from November 19 until December ... to view the selection of presale tickets available at ... to come out on October 14, and the tour in ... tickets are available for shows that will take place in ...
(Date:9/30/2014)... one third of medical and nursing students in developing ... own countries after graduation, while less than one fifth ... they are needed most, according to a new study. ... driving the current outbreak of Ebola in western Africa. ... three of the world,s poorest countries (Guinea, Sierra Leone ...
Breaking Medicine News(10 mins):Health News:Living Well Joins San Rafael Chamber of Commerce 2Health News:Living Well Joins San Rafael Chamber of Commerce 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:Bob Seger Presale Tickets: QueenBeeTickets.com Delights Fans with Discounted Tickets for All 20 Stops on Seger’s “Ride Out” Tour with The Silver Bullet Band 2Health News:Developing countries should enroll medical and nursing students from rural areas 2Health News:Developing countries should enroll medical and nursing students from rural areas 3
... , , EXTON, Pa., ... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that the ... of Generic Drugs (OGD) draft guidelines on bioequivalence (BE) for Vancocin(R) ... life-threatening bacterial infections of the gastrointestinal (GI) tract, Clostridium difficile ...
... ... versus Goliath struggle raging in the West, joins the stellar line-up at the ... and in Los Angeles (August 7 - 13). The film will also air ... Impact series on Planet Green, a network of Discovery Communications.,Split Estate maps a ...
... , , , ... (Nasdaq: CLRT ), a premier anatomic pathology and molecular testing ... results for the second quarter and six months ended June 30, 2009. ... second quarter of 2009 versus the second quarter of 2008, and a ...
... EAST RUTHERFORD, N.J., Aug. 4 Cambrex Corporation (NYSE: CBM ) ... Highlights , , Sales ... Reported sales declined by 9.8% for the quarter. , EBITDA ... year (see attached table). , Debt, net of cash was ...
... and MISSISSAUGA, ON, Aug. 4 /PRNewswire-FirstCall/ - Covidien (NYSE: ... products, and Nuvo Research Inc. (TSX:NRI), a Canadian drug ... Drug Administration (FDA) has set a new action date ... Pennsaid (diclofenac sodium) topical solution 1.5% w/w of November ...
... , WALTHAM, Mass., Aug. 4 Inverness ... leader in enabling individuals to take charge of their health ... management, today announced that it intends to offer $150 million ... of the notes will be guaranteed by certain of Inverness, ...
Cached Medicine News:Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 2Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 3Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 4Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 2Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 2Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 5Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 6Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 7Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 8Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 9Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 10Health News:Cambrex Reports Second Quarter 2009 Results 2Health News:Cambrex Reports Second Quarter 2009 Results 3Health News:Cambrex Reports Second Quarter 2009 Results 4Health News:Cambrex Reports Second Quarter 2009 Results 5Health News:Cambrex Reports Second Quarter 2009 Results 6Health News:Cambrex Reports Second Quarter 2009 Results 7Health News:Cambrex Reports Second Quarter 2009 Results 8Health News:Cambrex Reports Second Quarter 2009 Results 9Health News:Cambrex Reports Second Quarter 2009 Results 10Health News:Cambrex Reports Second Quarter 2009 Results 11Health News:Cambrex Reports Second Quarter 2009 Results 12Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 2Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 3Health News:Inverness Medical Innovations, Inc. Announces Offering of $150 Million of Senior Notes 2
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... onsite test! QuickScreen™ multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
Medicine Products: